Showing results (11-20 of 18) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Science Translational Medicine|July 29, 2011
IL-7 promotes T(H)1 development and serum IL-7 predicts clinical response to interferon-β in multiple sclerosisLi-Fen Lee, Robert Axtell, Guang Huan Tu, et al.Scientific Reports|June 12, 2019
Targeting CLDN18.2 by CD3 Bispecific and ADC Modalities for the Treatments of Gastric and Pancreatic CancerGuoyun Zhu, Davide Foletti, Xiaohui Liu, et al.Scientific Reports|November 9, 2019
Author Correction: Targeting CLDN18.2 by CD3 Bispecific and ADC Modalities for the Treatments of Gastric and Pancreatic CancerGuoyun Zhu, Davide Foletti, Xiaohui Liu, et al.Plos One|July 11, 2015
Site-Dependent Degradation of a Non-Cleavable Auristatin-Based Linker-Payload in Rodent Plasma and Its Effect on ADC EfficacyMagdalena Dorywalska, Pavel Strop, Jody A Melton-Witt, et al.Bioconjugate Chemistry|February 3, 2015
Effect of attachment site on stability of cleavable antibody drug conjugatesMagdalena Dorywalska, Pavel Strop, Jody A Melton-Witt, et al.Journal of Molecular Biology|May 1, 2012
Generating bispecific human IgG1 and IgG2 antibodies from any antibody pairPavel Strop, Wei-Hsien Ho, Leila M Boustany, et al.Proceedings of the National Academy of Sciences of the United States of America|July 27, 2006
DRB1*0401-restricted human T cell clone specific for the major proinsulin73-90 epitope expresses a down-regulatory T helper 2 phenotypeIvana Durinovic-Belló, Silke Rosinger, Jennifer A Olson, et al.Chemistry & Biology|February 27, 2013
Location matters: site of conjugation modulates stability and pharmacokinetics of antibody drug conjugatesPavel Strop, Shu-Hui Liu, Magdalena Dorywalska, et al.Pageof 2